CoreAge Rx advertises a compounded NAD+ injectable service through an online assessment model. Its product page gives a starting monthly price and describes clinician review and delivery. Those details make the offer identifiable, but they are not independent proof of the benefits claimed in its marketing.
CoreAge is the paid featured partner of I Love NAD+ and receives first placement in commercial comparisons. This review, checked September 23, 2026, keeps that relationship separate from the questions about the actual prescription, clinical evidence, and care arrangement.
THE USEFUL DISTINCTION
The NAD-specific offer is confirmed on public pages; clinical suitability and the finished prescription still require individual verification.
What the public page establishes
The NAD+ injectable page describes a prescription product, an online questionnaire, clinician review, and shipment if a prescription is issued. It advertises a starting price of $93 per month. Our partner link follows the NAD-specific destination linked from that product page, rather than a weight-management or unrelated treatment checkout.
We verified that the public link reaches a NAD landing page. We did not submit a patient history, complete a clinical assessment, or place an order. These are different levels of verification, and the review should not imply that checking a website amounts to testing the delivered care.
Evidence: CoreAge Rx: NAD+ injectable product page / CoreAge Rx: public catalog
The claims need a matching study
The company’s page makes broad claims about energy, cognition, recovery, and healthy aging. We treat those as provider marketing. Research about NAD biology or an oral precursor does not independently verify the clinical effectiveness of the compounded injectable preparation sold through this service.
A small IV metabolite pilot is also a different intervention and outcome from a home injection program. Our NAD explainer and evidence reader show why the study’s route, population, and endpoint must stay attached to its findings. We do not reproduce promotional timelines as expected results for readers.
Evidence: CoreAge Rx: NAD+ injectable product page / Grant et al.: 2019 IV NAD+ metabolome pilot / Martens et al.: 2018 oral NR crossover trial
The preparation and pharmacy questions
CoreAge describes compounding in the United States and provides general information about its pharmacy arrangements. Before accepting a prescription, ask which pharmacy will dispense it, how to verify that pharmacy’s licensing, and what storage and beyond-use instructions apply to the exact product. A network description does not identify the preparation in your package.
Compounded medication is not FDA-approved. The NAD safety article covers FDA’s warning about unsuitable ingredients for sterile compounding and reported reactions. That warning is context for evaluating any injectable offer, not an allegation that we found contamination in this company’s product.
Evidence: CoreAge Rx: pharmacy information / FDA: compounding and approval / FDA: suitable ingredients for sterile compounding
How to read the price
The advertised $93 monthly starting figure should be confirmed against the plan you are actually offered. Ask about the amount due now, the renewal interval, supplied quantity, shipping, supplies, clinician access, and cancellation or refund conditions. We have not verified a personalized invoice or insurance reimbursement.
The cost guide compares the billing language with other public offers. A low starting price should not be converted into a promise of an all-inclusive long-term total. Likewise, a more expensive service would not automatically have stronger clinical evidence or a better quality system.
Evidence: CoreAge Rx: NAD+ injectable product page / AgelessRx: NAD+ injections
Clinical oversight deserves specifics
Ask who assesses whether NAD+ is appropriate, what other explanations for symptoms should be considered, and how your medicines and medical history affect the discussion. Confirm that the clinician can treat you where you will physically be and that the pharmacy can serve that location.
For ongoing care, clarify how to report a problem, who reviews it, and what to do if the shipped product or directions are unclear. Our route comparison discusses responsibilities for injections and infusions without supplying a universal dose, volume, or schedule. Those instructions must come from the responsible clinician and pharmacist.
Evidence: HHS: telehealth licensing / FDA: BeSafeRx / CoreAge Rx: NAD+ injectable product page
Where this review stops
We did not audit sterile production, inspect a dispensed vial, measure patient outcomes, or test clinician response times. No medical-review credential or first-person treatment story is claimed. The public information supports a description of the service offer, not a conclusion that it is best for a particular person.
Read the AgelessRx review for another injectable service model and the Basis review for a distinctly different oral supplement category. CoreAge’s first position in the shortlist remains paid placement, explicitly disclosed rather than presented as a scientific score.
Evidence: CoreAge Rx: NAD+ injectable product page / AgelessRx: NAD+ injections / Elysium: Basis product and subscription terms
Open the source material
- CoreAge Rx: NAD+ injectable product page
Commercial description and starting price checked September 23, 2026. Benefit claims are not independent efficacy evidence.
- CoreAge Rx: public catalog
Company-level context and advertised offerings; no patient enrollment performed.
- Grant et al.: 2019 IV NAD+ metabolome pilot
Eight NAD+ recipients and three saline controls; short-term metabolite measurements, not a longevity or clinical efficacy trial.
- Martens et al.: 2018 oral NR crossover trial
Small, short-duration human study of oral NR; cannot establish effectiveness of injectable NAD+.
- CoreAge Rx: pharmacy information
Company explanation of its pharmacy network; verify the actual dispensing pharmacy for a prescription.
- FDA: compounding and approval
Compounded drugs are not FDA-approved; ingredient evidence does not certify the finished preparation.
- FDA: suitable ingredients for sterile compounding
Specific NAD+ safety communication: food-grade material, contamination risk and reported adverse events.
- AgelessRx: NAD+ injections
Advertised $79 first month on a three-month plan billed in full, then $149 per month. Confirm final terms; surveys are not controlled trials.
- HHS: telehealth licensing
General licensure guidance. Individual state availability must be checked directly.
- FDA: BeSafeRx
Online pharmacy checks, not certification of a particular brand.
- Elysium: Basis product and subscription terms
Oral NR plus pterostilbene supplement, not injectable NAD+. Marketing and purchase terms are separate from clinical trial results.
